BFG
KPTI icon

Bleakley Financial Group’s Karyopharm Therapeutics KPTI Stock Holding History

Bleakley Financial Group’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-3,277
Closed -$42.7K – 1062
2024
Q2 		$42.7K Buy
3,277
+343
+12% +$5.68K ﹤0.01% 986
2024
Q1 		$66.5K Buy
2,934
+405
+16% +$7.1K ﹤0.01% 954
2023
Q4 		$32.8K Buy
+2,529
New +$34.1K ﹤0.01% 935
2023
Q3 		– Sell
-1,064
Closed -$28.6K – 923
2023
Q2 		$28.6K Buy
+1,064
New +$45.8K ﹤0.01% 910

Other funds holding KPTI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Bleakley Financial Group's KPTI Position: Q3 2024 in Review

Bleakley Financial Group sold out of Karyopharm Therapeutics (KPTI) in Q3 2024, closing a stake of 3,277 shares — an estimated $42.7K sold.

Bleakley Financial Group first reported a position in KPTI in Q2 2023 and held it in 4 quarters. The position peaked at $66.5K in Q1 2024. 91 funds tracked by Wall St. Rank hold KPTI as of Q3 2024.

  • Bleakley Financial Group reported no remaining Karyopharm Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Bleakley Financial Group sold 3,277 Karyopharm Therapeutics shares in Q3 2024, an estimated $42.7K.
  • Bleakley Financial Group first reported a position in Karyopharm Therapeutics in Q2 2023 and held it in 4 quarters.
  • Bleakley Financial Group's Karyopharm Therapeutics position peaked at $66.5K in Q1 2024.
  • 91 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2024.

Based on Bleakley Financial Group's 13F filing for Q3 2024, filed 16 Oct 2024.